PL2393485T3 - Dwuwarstwowe tabletki zawierające elwitegrawir, kobicystat, emtrycytabinę i tenofowir - Google Patents
Dwuwarstwowe tabletki zawierające elwitegrawir, kobicystat, emtrycytabinę i tenofowirInfo
- Publication number
- PL2393485T3 PL2393485T3 PL10703766T PL10703766T PL2393485T3 PL 2393485 T3 PL2393485 T3 PL 2393485T3 PL 10703766 T PL10703766 T PL 10703766T PL 10703766 T PL10703766 T PL 10703766T PL 2393485 T3 PL2393485 T3 PL 2393485T3
- Authority
- PL
- Poland
- Prior art keywords
- cobicistat
- elvitegravir
- emtricitabine
- tenofovir
- bilayer tablets
- Prior art date
Links
- VERWQPYQDXWOGT-LVJNJWHOSA-N 4-amino-5-fluoro-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;[[(2r)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(propan-2-yloxycarbonyloxymethoxy)phosphoryl]oxymethyl propan-2-yl carbonate;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VERWQPYQDXWOGT-LVJNJWHOSA-N 0.000 title 1
- ZCIGNRJZKPOIKD-CQXVEOKZSA-N cobicistat Chemical compound S1C(C(C)C)=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2SC=NC=2)CC=2C=CC=CC=2)=C1 ZCIGNRJZKPOIKD-CQXVEOKZSA-N 0.000 title 1
- 229960002402 cobicistat Drugs 0.000 title 1
- JUZYLCPPVHEVSV-LJQANCHMSA-N elvitegravir Chemical compound COC1=CC=2N([C@H](CO)C(C)C)C=C(C(O)=O)C(=O)C=2C=C1CC1=CC=CC(Cl)=C1F JUZYLCPPVHEVSV-LJQANCHMSA-N 0.000 title 1
- 229960003586 elvitegravir Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15065209P | 2009-02-06 | 2009-02-06 | |
| US15065509P | 2009-02-06 | 2009-02-06 | |
| EP10703766.5A EP2393485B1 (en) | 2009-02-06 | 2010-02-04 | Bilayer tablets comprising elvitegravir, cobicistat, emtricitabine and tenofovir |
| PCT/US2010/023226 WO2010091197A2 (en) | 2009-02-06 | 2010-02-04 | Tablets for combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2393485T3 true PL2393485T3 (pl) | 2015-12-31 |
Family
ID=41722740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10703766T PL2393485T3 (pl) | 2009-02-06 | 2010-02-04 | Dwuwarstwowe tabletki zawierające elwitegrawir, kobicystat, emtrycytabinę i tenofowir |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US20100285122A1 (pl) |
| EP (1) | EP2393485B1 (pl) |
| JP (2) | JP5611242B2 (pl) |
| KR (2) | KR101645759B1 (pl) |
| CN (1) | CN102307573B (pl) |
| AP (1) | AP3250A (pl) |
| AR (1) | AR075369A1 (pl) |
| AU (1) | AU2010210598B2 (pl) |
| BR (1) | BRPI1008664A2 (pl) |
| CA (1) | CA2750521A1 (pl) |
| CL (1) | CL2011001885A1 (pl) |
| CY (1) | CY1116852T1 (pl) |
| DK (1) | DK2393485T3 (pl) |
| EA (2) | EA030123B1 (pl) |
| EC (1) | ECSP11011307A (pl) |
| ES (1) | ES2548886T3 (pl) |
| HR (1) | HRP20151009T1 (pl) |
| HU (1) | HUE025822T2 (pl) |
| IL (1) | IL214227A (pl) |
| MX (1) | MX2011008289A (pl) |
| NZ (1) | NZ594214A (pl) |
| PE (1) | PE20110994A1 (pl) |
| PL (1) | PL2393485T3 (pl) |
| PT (1) | PT2393485E (pl) |
| SG (3) | SG10201706215UA (pl) |
| SI (1) | SI2393485T1 (pl) |
| SM (1) | SMT201500266B (pl) |
| TW (1) | TWI444367B (pl) |
| UY (1) | UY32424A (pl) |
| WO (1) | WO2010091197A2 (pl) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101477822B1 (ko) | 2006-07-07 | 2015-01-02 | 길리애드 사이언시즈, 인코포레이티드 | 치료제의 약동학 특성의 모듈레이터 |
| PT3150586T (pt) * | 2007-02-23 | 2020-03-31 | Gilead Sciences Inc | Moduladores de propriedades farmacocinéticas de agentes terapêuticos |
| EA201591353A1 (ru) | 2008-05-02 | 2016-01-29 | Джилид Сайэнс, Инк. | Применение частиц твердого носителя для улучшения технологических характеристик фармацевтического агента |
| NZ610729A (en) | 2010-11-19 | 2015-10-30 | Gilead Sciences Inc | Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate |
| WO2012072580A1 (en) * | 2010-11-29 | 2012-06-07 | Formac Pharmaceuticals N.V. | Compressed formulations of ordered mesoporous silicas |
| PL2729130T3 (pl) * | 2011-07-07 | 2018-02-28 | Janssen Sciences Ireland Uc | Preparaty kombinowane darunawiru |
| AP3639A (en) | 2011-08-16 | 2016-03-13 | Gilead Sciences Inc | Tenofovir alafenamide hemifumarate |
| WO2013116730A1 (en) * | 2012-02-03 | 2013-08-08 | Gilead Sciences, Inc. | Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections |
| AU2012327170A1 (en) * | 2012-02-03 | 2013-08-22 | Gilead Sciences, Inc. | Therapeutic compounds |
| HK1204980A1 (en) * | 2012-03-01 | 2015-12-11 | Gilead Sciences, Inc. | Spray dried formulations |
| CN103830192A (zh) * | 2012-11-27 | 2014-06-04 | 安徽贝克生物制药有限公司 | 一种可粉末直接压片的富马酸替诺福韦二吡呋酯片剂及制备方法 |
| EA030003B1 (ru) | 2012-12-21 | 2018-06-29 | Джилид Сайэнс, Инк. | Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции |
| EP4233846B1 (en) | 2015-06-30 | 2024-12-04 | Gilead Sciences, Inc. | Pharmaceutical formulations |
| CN113546052A (zh) | 2015-11-09 | 2021-10-26 | 吉利德科学公司 | 治疗人免疫缺陷病毒的治疗组合物 |
| ES2806604T3 (es) | 2016-02-02 | 2021-02-18 | Sandoz Ag | Formas cristalinas de monofumarato de tenofovir alafenamida |
| EP4196096A1 (en) * | 2020-08-13 | 2023-06-21 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Gastro-resistant high-strength formulation containing posaconazole |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA923641B (en) | 1991-05-21 | 1993-02-24 | Iaf Biochem Int | Processes for the diastereoselective synthesis of nucleosides |
| US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| DE10153078A1 (de) * | 2001-10-30 | 2003-05-22 | Degussa | Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen |
| CN100375742C (zh) * | 2002-11-20 | 2008-03-19 | 日本烟草产业株式会社 | 4-氧代喹啉化合物及其用途 |
| JP3567162B1 (ja) * | 2002-11-20 | 2004-09-22 | 日本たばこ産業株式会社 | ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用 |
| US7176220B2 (en) * | 2002-11-20 | 2007-02-13 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
| PT1583542E (pt) | 2003-01-14 | 2008-09-17 | Gilead Sciences Inc | Composições e métodos para terapia de combinação antiviral |
| MY134672A (en) | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
| TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| TWI471145B (zh) * | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| ATE474560T1 (de) * | 2005-12-14 | 2010-08-15 | Cipla Ltd | Pharmazeutische kombination aus nucleotid und nucleosid-reverse-transkriptase-hemmern (wie tenofovir und lamivudin) in verschiedenen teilen der dosiereinheit |
| KR101477822B1 (ko) * | 2006-07-07 | 2015-01-02 | 길리애드 사이언시즈, 인코포레이티드 | 치료제의 약동학 특성의 모듈레이터 |
| PT3150586T (pt) * | 2007-02-23 | 2020-03-31 | Gilead Sciences Inc | Moduladores de propriedades farmacocinéticas de agentes terapêuticos |
-
2010
- 2010-02-04 PL PL10703766T patent/PL2393485T3/pl unknown
- 2010-02-04 SG SG10201706215UA patent/SG10201706215UA/en unknown
- 2010-02-04 NZ NZ594214A patent/NZ594214A/xx not_active IP Right Cessation
- 2010-02-04 EP EP10703766.5A patent/EP2393485B1/en not_active Revoked
- 2010-02-04 EA EA201491658A patent/EA030123B1/ru not_active IP Right Cessation
- 2010-02-04 SI SI201031019T patent/SI2393485T1/sl unknown
- 2010-02-04 KR KR1020117020652A patent/KR101645759B1/ko not_active Expired - Fee Related
- 2010-02-04 MX MX2011008289A patent/MX2011008289A/es active IP Right Grant
- 2010-02-04 SG SG2011056306A patent/SG173544A1/en unknown
- 2010-02-04 WO PCT/US2010/023226 patent/WO2010091197A2/en not_active Ceased
- 2010-02-04 CN CN2010800066460A patent/CN102307573B/zh not_active Expired - Fee Related
- 2010-02-04 AP AP2011005857A patent/AP3250A/xx active
- 2010-02-04 SG SG2014007744A patent/SG2014007744A/en unknown
- 2010-02-04 EA EA201190125A patent/EA021313B1/ru not_active IP Right Cessation
- 2010-02-04 US US12/700,608 patent/US20100285122A1/en not_active Abandoned
- 2010-02-04 PT PT107037665T patent/PT2393485E/pt unknown
- 2010-02-04 BR BRPI1008664A patent/BRPI1008664A2/pt not_active Application Discontinuation
- 2010-02-04 JP JP2011549268A patent/JP5611242B2/ja not_active Expired - Fee Related
- 2010-02-04 PE PE2011001449A patent/PE20110994A1/es active IP Right Grant
- 2010-02-04 DK DK10703766.5T patent/DK2393485T3/en active
- 2010-02-04 AU AU2010210598A patent/AU2010210598B2/en not_active Ceased
- 2010-02-04 HR HRP20151009TT patent/HRP20151009T1/hr unknown
- 2010-02-04 HU HUE10703766A patent/HUE025822T2/en unknown
- 2010-02-04 KR KR1020167020504A patent/KR101738325B1/ko not_active Expired - Fee Related
- 2010-02-04 ES ES10703766.5T patent/ES2548886T3/es active Active
- 2010-02-04 CA CA2750521A patent/CA2750521A1/en not_active Abandoned
- 2010-02-05 AR ARP100100328A patent/AR075369A1/es unknown
- 2010-02-06 TW TW099103651A patent/TWI444367B/zh not_active IP Right Cessation
- 2010-02-08 UY UY0001032424A patent/UY32424A/es not_active Application Discontinuation
-
2011
- 2011-07-21 IL IL214227A patent/IL214227A/en not_active IP Right Cessation
- 2011-08-05 CL CL2011001885A patent/CL2011001885A1/es unknown
- 2011-09-06 EC EC2011011307A patent/ECSP11011307A/es unknown
-
2014
- 2014-09-02 JP JP2014178005A patent/JP5911927B2/ja active Active
-
2015
- 2015-02-06 US US14/616,563 patent/US20150150810A1/en not_active Abandoned
- 2015-10-26 CY CY20151100953T patent/CY1116852T1/el unknown
- 2015-10-28 SM SM201500266T patent/SMT201500266B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2393485T1 (sl) | Dvoslojne tablete, ki vsebujejo elvitegravir, cobicistat, emtricitabin in tenofovir | |
| HUS2000009I1 (hu) | Kétrétegû tabletta készítmények | |
| SI2464342T1 (sl) | Farmacevtske formulacije proti zlorabi zdravil | |
| IL220509A (en) | Compressed pyridinylpyrolidone, a pharmaceutical preparation and combination | |
| ZA201201605B (en) | Highly concentrated pharmaceutical formulations comprising anti-cd20 antibody | |
| IL217224B (en) | Pyrazolopyrimides, pharmaceutical preparations containing them and their use | |
| ZA201200719B (en) | Pharmaceutical formulation | |
| EP2481739A4 (en) | DIHYDROPTERIDINONE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL USE | |
| PL2655375T3 (pl) | Pochodne pirymidynonu, ich wytwarzanie i ich farmaceutyczne zastosowanie | |
| IL270841A (en) | Increasing drug bioavailability in naltrexone therapy | |
| ZA201104348B (en) | Pharmaceutical preparation | |
| IL214402A0 (en) | Transdermal pharmaceutical preparations | |
| ZA201200366B (en) | 3-cyanoquinoline tablet formulations and uses thereof | |
| ZA200903858B (en) | Pharmaceutical dosage form | |
| PL2309983T3 (pl) | Farmaceutyczna postać podawania zawierająca tetrahydrobiopterynę | |
| GB0815972D0 (en) | Pharmaceutical preparation | |
| IL219617A0 (en) | Pharmaceutical solid dosage form | |
| IL229206A0 (en) | Preparation and tablet containing raltagravir | |
| PL2651390T3 (pl) | Orodyspersyjna tabletka farmaceutyczna na bazie zolpidemu | |
| GB0922537D0 (en) | Pharmaceutical preparation | |
| GB201115173D0 (en) | Pharmaceutical preparation | |
| GB201115179D0 (en) | Pharmaceutical preparation | |
| GB0906003D0 (en) | Oral drug formulation | |
| HU1000106V0 (en) | Dispenser for drugs in solid form | |
| HK1175118A (en) | Pharmaceutical solid dosage form |